| Study | Reason for exclusion |
|---|---|
| Albers 2016 | Post‐hoc analysis of observational study |
| Alvarez‐Cuesta 1994 | Intervention used in study (cat extract immunotherapy) is not anti‐IL‐5 therapy |
| Armentia 1992 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Austin 2016 | Aggregation of two clinical trials |
| Ayres 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bel 2014 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
| Berger 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Blanken 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Blanken 2013 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
| Boulet 1997 | Intervention used in study (anti‐IgE antibody e25) is not anti‐IL‐5 therapy |
| Bousquet 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bousquet 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Brightling 2014 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Brown 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Brusselle 2016 | Aggregation of two clinical trials |
| Bryant 1975a | Not a RCT |
| Bryant 1975b | Not a RCT |
| Buhl 2000a | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
| Buhl 2000b | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
| Buhl 2002 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bush 1985 | Intervention used in study (soybean oil) is not anti‐IL‐5 therapy |
| Busse 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Busse 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Busse 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Buttner 2003 | Treatment < 16 weeks |
| Caffarelli 2000 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Canvin 2016 | Aggregation of two clinical trials |
| Castro 2011 | < 16 weeks in length |
| Castro 2014b | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Chandra 1989 | Intervention used in study (various foods) is not anti‐IL‐5 therapy |
| Chervinsky 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Clavel 1998 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Corren 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Corren 2010 | Intervention used in study (il‐4ralpha antagonist) is not anti‐IL‐5 therapy |
| Cullell‐Young 2002 | Not a RCT |
| Dasgupta 2016 | Participants did not have a diagnosis of asthma (COPD patients) |
| De Boever 2014 | Intervention used in study (anti‐IL‐13 mab) is not anti‐IL‐5 therapy |
| Djukanovic 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Ebner 1989 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Eckman 2010 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| El‐Nawawy 2000 | Not a RCT |
| EUCTR2012‐004385‐17‐BE | The study participants did not have asthma |
| EUCTR2014‐002666‐76‐GB | Treatment period < 16 weeks |
| EUCTR2014‐003162‐25‐DE | The study participants did not have asthma |
| EUCTR2015‐001152‐29‐BE | Not an RCT and endpoints are not applicable as this is a long‐term access programme |
| EUCTR2015‐003697‐32‐NL | Not placebo‐controlled. Single treatment arm only |
| EUCTR2016‐001831‐10‐NL | No placebo arm/single treatment arm and treatment duration < 16 weeks |
| EUCTR2016‐002405‐19‐DE | Participants do not have a diagnosis of asthma, no placebo arm, treatment duration < 16 weeks |
| Fahy 1997 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Fahy 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Ferrguson 2016 | Treatment duration < 16 weeks in length |
| Finn 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Flood‐Page 2003 | Treatment < 16 weeks |
| Flood‐Page 2007 | Treatment < 16 weeks |
| Frew 1998 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Garcia 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Gauvreau 2011 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
| Gauvreau 2014a | Intervention used in study ( anti‐tslp) is not anti‐IL‐5 therapy |
| Gauvreau 2014b | Intervention used in study (ox40l antagonism) is not anti‐IL‐5 therapy |
| Gauvreau 2014c | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
| Gauvreau 2015a | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
| Gauvreau 2015b | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
| Gevaert 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Gordon 1972 | Intervention used in study is not anti‐IL‐5 therapy |
| Greenberg 1991 | Participants do not have a diagnosis of asthma |
| Gunsoy 2016 | Not a randomised, placebo‐controlled trial |
| Han 2009 | Intervention used in study ( jade screen powder) is not anti‐IL‐5 therapy |
| Hanania 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hanania 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hanania 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Hanania 2015 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Harris 2016 | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
| Hendeles 2015 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hill 1982 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Hodsman 2013 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
| Holgate 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hoshino 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Humbert 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Humbert 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Humbert 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Jacquemin 1995 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Jutel 2005 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Kang 1988 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Kips 2003 | Treatment < 16 weeks |
| Kon 2001 | Intervention used in study (anti‐cd4) is not anti‐IL‐5 therapy |
| Kopp 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Kopp 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Kulus 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Lanier 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Lanier 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Laviolette 2013 | Treatment < 16 weeks |
| Leckie 2000 | Treatment < 16 weeks |
| Leynadier 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Li 2016 | Review article, not a RCT |
| Lizaso 2008 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Lugogo 2016 | Not a randomised, placebo‐controlled trial |
| Maspero 2016 | Combined secondary analysis of two trials: NCT01287039 and NCT01285323 |
| Massanari 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Massanari 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Metzger 1998 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Milgrom 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Milgrom 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Modlin 1977 | Participants do not have diagnosis of asthma |
| Moss 1987 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Nair 2009 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
| Nair 2016 | All participants do not have a diagnosis of asthma |
| NCT00783289 2008 | Treatment duration < 16 weeks |
| NCT00802438 | Non randomised study |
| NCT01290887 2011 | Study does not include a placebo arm |
| NCT01366521 | Phase 2 study comparing three doses of mepolizumab. This trial does not have a placebo arm |
| NCT01471327 | Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose SB‐240563 administered intravenously to Japanese healthy male participants. People with asthma were not included in the study. |
| NCT01691859 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered subcutaneously (no control group) |
| NCT01842607 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered subcutaneously (no control group) |
| NCT02075255 2014 | Focus of trial is on oral steroid reduction |
| NCT02135692 | This study does not include a placebo group. Multi‐center, open‐label, long‐term study of subcutaneously (SC) administered mepolizumab 100 mg in addition to standard of care (SOC), in participants with severe eosinophilic asthma |
| NCT02258542 2014 | Not a RCT (an extension study with no placebo arm) |
| NCT02293265 | Aim of study is to provide a 'reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab'. No pharmaceutical intervention in study |
| NCT02417961 2015 | Not a RCT |
| NCT02501629 2015 | Focus of trial is on oral steroid reduction |
| NCT02559791 | Not placebo‐controlled ‐ single treatment arm only |
| NCT02808819 2016 | Not a RCT |
| NCT02814643 2016 | Treatment duration < 16 weeks |
| NCT02869438 | Treatment duration < 16 weeks |
| NCT02937168 | Treatment duration < 16 weeks |
| NCT02968914 | Not a placebo‐controlled trial |
| NCT03014674 | Not a placebo‐controlled trial and treatment duration < 16 weeks |
| NCT03021304 | No placebo arm/single treatment arm, treatment duration < 16 weeks |
| Newbold 2016 | Not a RCT |
| Niven 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Noga 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Noga 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Noonan 2013 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Nowak 2015 | Treatment < 16 weeks |
| Oba 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Oh 2013 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
| Ohashi 1997 | Participants do not have a diagnosis of asthma |
| Ohman 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Ohta 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Ong 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Park 1998 | Not a RCT |
| Parker 2010 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
| Pauli 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Pavord 2012b | Posthoc analysis of Pavord 2012a and Ortega 2014 stratified by prior use of anti‐IgE therapy |
| Pelaia 2016 | Study is not a RCT |
| Pham 2016 | An analysis of sera collected from asthma patients enrolled in two clinical studies: NCT00659659 and NCT00783289 |
| Piper 2012 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Piper 2013 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Pouliquen 2015 | Study has no placebo arm or clinical endpoints |
| Pouliquen 2016 | Aggregation of two clinical trials |
| Prazma 2016 | Study is not a randomised, placebo controlled trial |
| Prieto 2006 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Pui 2010 | Intervention used in study (air/diesel exhaust +/‐ antioxidant) is not anti‐IL‐5 therapy |
| Ranade 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Rose 2009 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
| Sakamoto 1984 | Not a RCT |
| Scheerens 2011 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Scheerens 2012 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Scheerens 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Siergiejko 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Silk 1998 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
| Silkoff 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Simoes 2007 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
| Singh 2010 | Intervention used in study (anti‐IL‐13) is not anti‐IL‐5 therapy |
| Slavin 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Soler 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Sorkness 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Sthoeger 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Sugaya 1994 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
| Swanson 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Szymaniak 1998 | Not a RCT |
| Tanaka 1993 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
| Terr 1969 | Study predates monoclonal treatments |
| Van Rensen 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Vignola 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Virchow 2016 | Aggregation of two clinical trials |
| Wang 2015 | Pharmacometrics assessment of phase IIb data to characterize the exposure‐response relationship with Benralizumab in adults with asthma. |
| Wark 2003 | Intervention used in study (itraconazole) is not anti‐IL‐5 therapy |
| Weinstein 2016 | Combined secondary analysis of two trials: NCT01287039 and NCT01285323 |
| Wenzel 2009 | Intervention used in study (golimumab) is not anti‐IL‐5 therapy |
| Wenzel 2013a | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Wenzel 2013b | Interventionused in study (dupilumab) is not anti‐IL‐5 therapy |
| Wenzel 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Yan 2015 | Participants do not have a diagnosis of asthma |
| Zetterstrom 1972 | Participants do not all have diagnosis of asthma |
| Zhu 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Zielen 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
RCT: randomised controlled trial